Immunotherapy before surgery for EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies giving toripalimab (an immune therapy drug) before lung surgery for EGFR-mutated, operable (resectable) non-squamous non-small cell lung cancer. It aims to see whether shrinking or controlling the cancer before surgery can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer that has not been treated before
- Your cancer must be stage II to IIIB (with specific lymph-node involvement) and still operable with surgery
- Your tumor test shows an EGFR mutation called either 19del or L858R
- You can provide tumor tissue (or agree to blood testing) for PD-L1 and EGFR testing
- You must be well enough for treatment and surgery (good physical function and lung/heart tests)
- You have no major treatment blockers (such as prior cancer medicines like chemo or immunotherapy, or certain immune conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (sintilimab) before surgery helps people with a specific type of lung cancer (EGFR-mutant, non-small cell) that is at a stage where surgery can be considered. The goal is to improve outcomes by shrinking the tumor before the operation.
This phase 3 trial tests adding toripalimab (an immunotherapy) to standard chemotherapy after surgery for certain stage II to IIIB (N2) lung cancers. It aims to lower the chance the cancer comes back by treating tiny remaining cancer cells and supporting your immune system.
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
This trial tests whether adding chemotherapy and an immunotherapy drug (sintilimab) to targeted therapy (limertinib) before surgery works better than continuing targeted therapy alone. It is for people with stage II-IIIB EGFR-mutant lung cancer that can be removed with surgery.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.